Li N, Geng S, Dong ZZ, Jin Y, Ying H, Li HW, Shi L. A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy. Mol Cancer. 2024;23(1):117.

Article  PubMed  PubMed Central  Google Scholar 

Yin N, Li X, Zhang X, Xue S, Cao Y, Niedermann G, Lu Y, Xue J. Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities. Signal Transduct Target Therapy. 2024;9(1):126.

Article  Google Scholar 

Posey AD Jr., Young RM, June CH. Future perspectives on engineered T cells for cancer. Trends cancer 2024.

Valcz G, Buzás EI, Gatenby RA, Újvári B, Molnár B. Small extracellular vesicles from surviving cancer cells as multiparametric monitoring tools of measurable residual disease and therapeutic efficiency. Biochim et Biophys acta Reviews cancer. 2024;1879(2):189088.

Article  CAS  Google Scholar 

Ashour D, Le Gouge K, Rainer PP, Mariotti-Ferrandiz E, Campos Ramos G. Exploring T cell receptor repertoires in myocardial diseases. Circul Res. 2024;134(12):1808–23.

Article  CAS  Google Scholar 

Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Sci (New York NY). 2015;348(6230):62–8.

Article  CAS  Google Scholar 

June CH, Sadelain M. Chimeric Antigen receptor therapy. N Engl J Med. 2018;379(1):64–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith TT, Stephan SB, Moffett HF, McKnight LE, Ji W, Reiman D, Bonagofski E, Wohlfahrt ME, Pillai SPS, Stephan MT. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 2017;12(8):813–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Reviews Clin Oncol 2024.

Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang T, Tai Z, Miao F, Zhang X, Li J, Zhu Q, Wei H, Chen Z. Adoptive cell therapy for solid tumors beyond CAR-T: current challenges and emerging therapeutic advances. J Controlled Release: Official J Controlled Release Soc. 2024;368:372–96.

Article  CAS  Google Scholar 

Xin T, Cheng L, Zhou C, Zhao Y, Hu Z, Wu X. In-Vivo Induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy. Front Oncol. 2022;12:809754.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shin MH, Oh E, Kim Y, Nam DH, Jeon SY, Yu JH, Minn D. Recent advances in CAR-Based solid Tumor Immunotherapy. Cells 2023, 12(12).

Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16(9):566–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cho JH, Collins JJ, Wong WW. Universal Chimeric Antigen Receptors for multiplexed and Logical Control of T Cell Responses. Cell. 2018;173(6):1426–e14381411.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao J, Lin Q, Song Y, Liu D. Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol. 2018;11(1):132.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh RB, Cho W, Liu C, Naderi A, Surico PL, Kahale F, Dohlman TH, Chauhan SK, Dana R. Immunopathological mechanisms and clinical manifestations of ocular graft-versus-host disease following hematopoietic stem cell transplantation. Bone Marrow Transplant 2024.

Huang X, Zhang W. Overcoming T cell exhaustion in Tumor Microenvironment via Immune Checkpoint Modulation with Nano-Delivery systems for enhanced immunotherapy. Small Methods 2023:e2301326.

Walton ZE, Frigault MJ, Maus MV. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy. Expert Opin Pharmacother. 2024;25(3):263–79.

Article  CAS  PubMed  Google Scholar 

Nelson MH, Knochelmann HM, Bailey SR, Huff LW, Bowers JS, Majchrzak-Kuligowska K, Wyatt MM, Rubinstein MP, Mehrotra S, Nishimura MI et al. Identification of human CD4(+) T cell populations with distinct antitumor activity. Sci Adv 2020, 6(27).

Qi Y, Li Y, Wang H, Wang A, Liu X, Liang Z, Gao Y, Wei L. Natural killer cell-related anti-tumour adoptive cell immunotherapy. J Cell Mol Med. 2024;28(11):e18362.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ni Z, Knorr DA, Bendzick L, Allred J, Kaufman DS. Expression of chimeric receptor CD4ζ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo. Stem Cells. 2014;32(4):1021–31.

Article  CAS  PubMed  Google Scholar 

Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, et al. Use of CAR-Transduced Natural Killer cells in CD19-Positive lymphoid tumors. N Engl J Med. 2020;382(6):545–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li T, Niu M, Zhang W, Qin S, Zhou J, Yi M. CAR-NK cells for cancer immunotherapy: recent advances and future directions. Front Immunol. 2024;15:1361194.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li M, Jiang P, Wei S, Wang J, Li C. The role of macrophages-mediated communications among cell compositions of tumor microenvironment in cancer progression. Front Immunol. 2023;14:1113312.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mishra AK, Malonia SK. Advancing cellular immunotherapy with macrophages. Life Sci. 2023;328:121857.

Article  CAS  PubMed  Google Scholar 

Anderson NR, Minutolo NG, Gill S, Klichinsky M. Macrophage-based approaches for Cancer Immunotherapy. Cancer Res. 2021;81(5):1201–8.

Article  CAS  PubMed  Google Scholar 

Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang L, Tian L, Dai X, Yu H, Wang J, Lei A, Zhu M, Xu J, Zhao W, Zhu Y, et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J Hematol Oncol. 2020;13(1):153.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Q, Li J, Zheng H, Yang S, Hua Y, Huang N, Kleeff J, Liao Q, Wu W. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Mol Cancer. 2023;22(1):28.

Article  PubMed  PubMed Central  Google Scholar 

Li X, Li W, Xu L, Song Y. Chimeric antigen receptor-immune cells against solid tumors: structures, mechanisms, recent advances, and future developments. Chin Med J 2023.

Teng KY, Mansour AG, Zhu Z, Li Z, Tian L, Ma S, Xu B, Lu T, Chen H, Hou D, et al. Off-the-Shelf prostate Stem Cell Antigen-Directed chimeric Antigen receptor Natural Killer Cell Therapy to treat pancreatic Cancer. Gastroenterology. 2022;162(4):1319–33.

Article  CAS  PubMed  Google Scholar 

Tang C, Jing W, Han K, Yang Z, Zhang S, Liu M, Zhang J, Zhao X, Liu Y, Shi C, et al. mRNA-Laden lipid-nanoparticle-enabled in situ CAR-Macrophage Engineering for the eradication of Multidrug-Resistant Bacteria in a Sepsis Mouse Model. ACS Nano. 2024;18(3):2261–78.

Article  CAS  PubMed  Google Scholar 

Pardi N, Weissman D. Nucleoside Modified mRNA vaccines for infectious diseases. Methods Mol Biology (Clifton NJ). 2017;1499:109–21.

Article  CAS  Google Scholar 

Wang C, Zhang Y, Dong Y. Lipid Nanoparticle-mRNA formulations for therapeutic applications. Acc Chem Res. 2021;54(23):4283–93.

Article  CAS  PubMed  PubMed Central  Google Scholar